Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway

Abstract excerpt

Nonalcoholic steatohepatitis (NASH) is a combination of hepatic steatosis, inflammation, and fibrosis, and it often follows simple hepatic steatosis in nonalcoholic fatty liver disease (NAFLD). However, no pharmacological treatment is currently available for NASH. Given the important role of TFEB (transcription factor EB) in regulating the macroautophagy/autophagy-lysosomal pathway, TFEB is potentially a novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Diet, Metabolism, and Disease
• Share to Metabolism, Diabetes, and Cancer
• Share to Natural Antidiabetic Agents Studies